There are 30.1 million Americans with diabetes, 380 million worldwide means a vast, wide-open market.
It’s a public health crisis like few others – 9.4% of Americans have diabetes. And, the drug that keeps them alive – insulin – is made by just three multinational corporations.
In fact, 3 pharmaceutical giants own control over 90% of the world’s insulin market.
Now, a novel breakthrough could level the treatment playing field for diabetics with a new technology that treats diabetes at the cellular level by targeting the health of the malfunctioning beta cells that cause diabetes.
This technology uses a spark to regenerate cells, much in the way nature does with animals, such as amphibians, which are able to regrow organs and limbs.
Like cracking the genetic code, the regeneration science behind this novel technology is a true 21st century story. It’s another example of science fiction becoming reality.
Science Suggests Bioelectric Medicines Are The Wave Of The Future
Microcurrent is a therapy in which Cell MedX’s breakthrough eBalance technology sends a pulsating stream of electrons in relatively low concentrations throughout the body.
The eBalance device is noninvasive, and the electrical currents it delivers mimic the endogenous, or deep tissue, electric energy of the human body.
It’s “microcurrent” because eBalance uses a direct current of about 3 milliamperes.
And, because it sends micro currents deep into the body, eBalance is very different from electric pulse muscle stimulators, such as TENS.
And, this is where this technology separates itself from the pack and distinguishes itself as a potentially life-altering breakthrough.
That said, the muscle stimulation market could portend how huge a trend eBalance could become.
That’s because the global muscle stimulation is forecast to grow to $853 million during the next five years.
Since the 1980s, diabetic neuropathy and non-healing wounds have been successfully treated using programmed delivery of microcurrents.
Neuropathy is a side effect of diabetes. It’s when the brain misfires and causes tingling or severe pain in the hands and feet. It can be crippling.
But, it is its non-healing wounds that are the true scourge of diabetes.
That because most humans, over the course of a year, get a nick, or a scratch or a cut. But, diabetics’ high glucose levels suppress white blood cells’ healing power, and their power to destroy bacteria.
For them, bacterial infections can be brutal.
According to some reports, about 1 in 4 diabetics will suffer foot ulcers, which are painful sores that could ultimately lead to foot amputations.
In fact, the American Journal of Managed Care estimates there are about 230 amputations each day in the United States as a result of diabetes.
Based on first-in-human observations, a specific set of bioelectric signals – of known waveform, frequency, amplitude, and duration – can be pulsed into the body to target beta cells and a protein known as glucose transporter type 4.
Beta cells make insulin, and it’s GLUT4 that transports insulin to the rest of the body when the beta cells tell it to.
Damaged beta cells contain damaged GLUT4.
In diabetics, when the body demands insulin it’s like trying to start a car that’s out of gas. Everything seems to be working, the radio is on, the lights work, the ignition works, but the car won’t start.
But, the breakthrough with eBalance is that it delivers the proper microcurrent to beta cells and GLUT4, so they release the insulin diabetics so
Massive Cost Is Not A Surprise For People In The Know
The government knows how brutal insulin costs are. Between 2007 and 2017, total Medicare Part D spending on insulin increased 840%, from $1.4 billion to $13.3 billion.
Other interesting facts from the American Diabetes Association include:
Grandview Research predicts that electroceutical/bioelectric medicine market will be a $35.5 billion by 2025.
Bioelectric medicine looks as if it’s going to be one of the 21st century’s top healthcare trends. Be sure to sign up for our newsletter to learn more about the companies on the leading edge of this transformative shift in healthcare
It’s free to sign up and you’ll be among the first to learn of events that could trigger a stampede of new investor interest.